Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR001 in Relapsed/Refractory Solid Tumors
NCT06150885Phase 2Recruiting
- Sponsor
- Ever Supreme Bio-Technology
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- mRNA Therapeutics, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of HLA-G-CAR.BiTE allogeneic γδ T cells in solid tumor, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), glioblastoma multiforme (GBM), sponsored by Ever Supreme Bio-Technology. Started Sep 2024; status: recruiting.
02
Drugs
HLA-G-CAR.BiTE allogeneic γδ T cells
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT06150885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150885.